Allarity Therapeutics, Inc.
ALLR
$1.28
$0.032.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -46.49% | -44.51% | -44.73% | 24.33% | 15.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -4.39% | -4.39% | -4.39% | 0.25% | 0.25% |
| Total Operating Expenses | -34.84% | -22.85% | -26.30% | 12.61% | 1.06% |
| Operating Income | 36.86% | 24.96% | 28.13% | -12.61% | -1.06% |
| Income Before Tax | 49.60% | 52.70% | 54.89% | 19.76% | -111.66% |
| Income Tax Expenses | -- | -- | -- | 100.00% | -577.22% |
| Earnings from Continuing Operations | 48.81% | 51.94% | 54.19% | 18.49% | -106.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.81% | 51.94% | 54.19% | 18.49% | -106.98% |
| EBIT | 36.86% | 24.96% | 28.13% | -12.61% | -1.06% |
| EBITDA | 52.82% | 41.55% | 28.34% | -12.50% | -1.02% |
| EPS Basic | 91.98% | 94.45% | 93.77% | 79.14% | -193.98% |
| Normalized Basic EPS | 77.82% | 89.15% | 87.60% | 50.94% | -8.87% |
| EPS Diluted | 91.98% | 94.45% | 93.77% | 79.14% | -193.98% |
| Normalized Diluted EPS | 77.82% | 89.15% | 87.60% | 50.94% | -8.87% |
| Average Basic Shares Outstanding | 91.99% | 254.45% | 795.91% | 2,105.26% | 6,428.60% |
| Average Diluted Shares Outstanding | 91.99% | 254.45% | 795.91% | 2,105.26% | 6,428.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |